B2
`A1
`B2
`A1
`A1
`
`20130917
`20080110
`20120703
`20080320
`20121025
`
`US 8536134
`US 20080009436
`US 8211855
`US 20080070834
`US 20120270805
`PRIORITY APPLN. INFO.:
`
`20070918
`US 2007-857223
`20071115
`US 2007-940652
`20120628
`US 2012-13536479
`A2 20050713
`US 2005-181178
`A2 20050713
`US 2005-181187
`A2 20050713
`US 2005-181409
`A2 20050713
`US 2005-181428
`A2 20050713
`US 2005-181509
`A3 20051019
`US 2005-255821
`A1 20070918
`US 2007-857223
`ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
`AB
`A composition is disclosed herein comprising from about 0.001% to about 0.4%
`cyclosporin A, castor oil, and a surfactant selected from the group
`consisting of ale. ethoxylated, ales., alkyl glycosides, alkyl
`polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers,
`carboxylated ale. or alkylphenol ethoxylates, carboxylic adds/fatty acids,
`cellulose derivs., ethoxylated ales., ethoxylated alkylphenols,
`ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty
`acids, ethoxylated fatty esters and oils, fatty ales., fatty esters,
`glycol esters, lanolin-based derivs., lecithin and lecithin derivs.,
`lignin and lignin derivs.. Me esters, monoglycerides and derivs.,
`phospholipids, polyacrylic acids, polyethylene glycols, polyethylene
`oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric
`surfactants, polypropylene oxides, propoxylated ales., propoxylated alkyl
`phenols, propoxylated fatty acids, protein-based surfactants, sarcosine
`derivs., silicone-based surfactants, sorbitan derivs., stearates, sucrose
`and glucose esters and derivs., and combinations thereof. For example,
`emulsion was prepared containing cyclosporin A 0.1%, castor oil 1%, clove
`oil 0.7%, Polysorbate-80 1%, diglycerol 0.7%, glycerin 2%,
`CM-cellulose 0.5%, sodium hydroxide to adjust pH (7.2) and water as
`needed.
`THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
`OS.CITING REF COUNT:
`(2 CITINGS)
`REFERENCE COUNT:
`THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`CAPLUS COPYRIGHT 2 013 ACS on STN
`2007:58577 CAPLUS
`146:149007
`Composition comprising cyclosporin A
`Chang, James N.; Olejnik, Orest; Firestone, Bruce A.
`Allergan, Inc., USA
`PCT Int. Appl., 32 pp.
`CODEN: PIXXD2
`Patent
`English
`3
`
`1
`89
`
`ANSWER 5 OF 5
`LI
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`TITLE:
`INVENTOR(S):
`PATENT ASSIGNEE(S):
`SOURCE:
`DOCUMENT TYPE:
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`PATENT INFORMATION:
`KIND DATE
`PATENT NO.
`A2
`20070118
`WO 2007008894
`A3
`20070628
`WO 2007008894
`W:
`AE, AG, AL, AM, AT, AU, AZ,
`CN, CO, CR, CU, CZ, DE, DK,
`GE, GH, GM, HN, HR, HU, ID,
`KR, KZ, LA, LC, LK, LR, LS,
`MW, MX, MZ, NA, NG, NI, NO,
`SC, SD, SE, SG, SK, SL, SM,
`US, UZ, VC, VN, ZA, ZM, ZW
`
`DATE
`APPLICATION NO.
`20060712
`WO 2006-US26881
`BA, BB, BG, BR, BW, BY, BZ, CA, CH,
`DM, DZ, EC, EE, EG, ES, FI, GB, GD,
`IL, IN, IS, JP, KE, KG, KM, KN, KP,
`LT, LU, LV, LY, MA, MD, MG, MK, MN,
`NZ, OM, PG, PH, PL, PT, RO, RS, RU,
`SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
`
`0202
`
` EXHIBIT 1025 (Part 2 of 4)
`
`

`
`BG, CH,
`LT, LU,
`CI, CM,
`LS, MW,
`MD, RU,
`A1
`B2
`A1
`B2
`A1
`A1
`B2
`A1
`A1
`A1
`A2
`CH,
`LT,
`T
`A2
`A1
`B2
`A1
`A1
`B2
`
`CY, CZ, DE,
`LV, MC, NL,
`GA, GN, GQ,
`MZ, NA, SD,
`TJ, TM, AP,
`20070118
`20071120
`20070118
`20071002
`20070118
`20070118
`20070410
`20070118
`20070118
`20070118
`20080326
`CY, CZ, DE,
`LU, LV, MC,
`20090115
`20110118
`20070628
`20130917
`20080320
`20080828
`20121016
`
`GB,
`SI,
`
`RW: AT, BE,
`IS, IT,
`CF, CG,
`GM, KE,
`KG, KZ,
`US 20070015690
`US 7297679
`US 20070015710
`US 7276476
`US 20070015691
`US 20070015692
`US 7202209
`US 20070015693
`AU 2006268264
`CA 2602452
`EP 1901711
`AT, BE, BG,
`R. *
`IS, IT, LI,
`JP 2009501228
`BR 2006013533
`US 20070149447
`US 8536134
`US 20080070834
`US 20080207494
`US 8288348
`PRIORITY APPLN. INFO.:
`
`GB, GR, HU, IE,
`DK, EE, ES, FI, FR,
`TR, BF, BJ,
`PL, PT, RO, SE, SI,
`SK,
`TG, BW, GH,
`TD,
`GW, ML, MR, NE, SN,
`AM, AZ, BY,
`ZW,
`SL, SZ, TZ, UG, ZM,
`EA, EP, OA
`20050713
`US 2005-181178
`20050713
`US 2005-181187
`20050713
`US 2005-181409
`20050713
`US 2005-181428
`20050713
`US 2005-181509
`20060712
`AU 2006-268264
`20060712
`CA 2006-2602452
`20060712
`EP 2006-786892
`GR, HU, IE,
`DK, EE, ES, FI, FR,
`SK, TR
`NL, PL, PT, RO, SE,
`20060712
`JP 2008-521528
`20060712
`BR 2006-13533
`20070228
`US 2007-679934
`20071115
`US 2007-940652
`20071213
`US 2007-917448
`A
`20050713
`US 2005-181178
`A
`20050713
`US 2005-181187
`20050713
`US 2005-181409
`A
`20050713
`US 2005-181428
`A
`20050713
`US 2005-181509
`A
`20060712
`WO 2006-US26881
`W
`ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
`Cyclosporin A compns. are disclosed herein comprising an oil and a
`AB
`These are useful in the treatment of dry eye disease. Thus,
`surfactant.
`composition was prepared containing cyclosporin A 0.1, castor oil 1,
`clove oil
`0.7, polysorbate-80 1, diglycerol 0.7, glycerin 2, CM-cellulose 0.5
`and water as needed.
`OS.CITING REF COUNT:
`THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
`6
`(6 CITINGS)
`
`=> d his
`(FILE 'HOME' ENTERED AT 23:44:39 ON 01 OCT 2013)
`FILE
`CAPLUS, MEDLINE, EMBASE, BIOSIS' ENTERED AT 23:44:57 ON 01 OCT 2013
`5 CYCLOSPORIN AND CASTOR AND POLYSORBATE AND PEMULEN AND (GLYCERI
`
`LI
`=> logoff h
`COST IN U.S. DOLLARS
`FULL ESTIMATED COST
`SESSION WILL BE HELD FOR 120 MINUTES
`STN INTERNATIONAL SESSION SUSPENDED AT 23:48:15 ON 01 OCT 2013
`
`SINCE FILE
`ENTRY
`37.83
`
`TOTAL
`SESSION
`38.07
`
`0203
`
`

`
`Search Notes
`
`Application/Control No.
`
`13967163
`
`Examiner
`
`Applicant(s)/Patent Under
`Reexamination
`ACHEAMPONG ET AL.
`
`Art Unit
`
`MARCELA M CORDERO GARCIA
`
`1658
`
`CPC- SEARCHED
`
`Symbol
`
`Date
`
`Examiner
`
`CPC COMBINATION SETS - SEARCHED
`
`Symbol
`
`Date
`
`Examiner
`
`US CLASSIFICATION SEARCHED
`
`Class
`none
`
`none
`
`Subclass
`
`Date
`10/2/2013
`
`Examiner
`MMCG
`
`SEARCH NOTES
`
`Search Notes
`
`SIN search (attached)
`EAST updated (attached)
`also ran PALM Inventor search
`
`Date
`10/3/2013
`10/2/2013
`10/2/2013
`
`Examiner
`MMCG
`MMCG
`MMCG
`
`INTERFERENCE SEARCH
`
`US Class/
`CPC Symbol
`
`US Subclass / CPC Group
`
`Date
`
`Examiner
`
`U.S. Patent and Trademark Office
`
`Part of Paper No. : 20130927
`
`0204
`
`

`
`g^qgjjj^t^tate: 09/12/2013
`Doc description: Information Disclosure Statement (IDS) Filed
`
`13967163-GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`2013-08-14
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MM.C.G./
`U.S.PATENTS
`
`Examiner Cite
`Initial*
`No
`
`Patent Number
`
`Kind
`Code1
`
`Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`1
`
`3278447
`
`1966-10-11
`
`Thomas McNicholas
`
`2
`
`4388229
`
`1983-06-14
`
`Cherng-Chyi Fu
`
`3
`
`4388307
`
`1983-06-14
`
`Thomas Cavanak
`
`4
`
`4614736
`
`1986-09-30
`
`Delevallee et al
`
`5
`
`4649047
`
`1987-03-10
`
`Renee Kaswan
`
`6
`
`4764503
`
`1988-08-16
`
`Roland Wenger
`
`7
`
`4814323
`
`1989-03-21
`
`Andrieu et al
`
`8
`
`4839342
`
`1989-06-13
`
`Renee Kaswan
`
`0205
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`17618-US-BCON6-AP
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, MM.C.G./
`
`9
`
`4970076
`
`1990-11-13
`
`David Horrobin
`
`10
`
`4990337
`
`1991-02-05
`
`Kurihara et al
`
`11
`
`4996193
`
`1991-02-26
`
`Hewitt et al
`
`12
`
`5047396
`
`1991-09-10
`
`Orban et al
`
`13
`
`5051402
`
`1991-09-24
`
`Kurihara et al
`
`14
`
`5053000
`
`1991-10-01
`
`Booth et al
`
`15
`
`5286730
`
`1994-02-15
`
`Caufield et al
`
`16
`
`5286731
`
`1994-02-15
`
`Caufield et al
`
`17
`
`5294604
`
`1994-03-15
`
`Nussenblatt et al
`
`18
`
`5296158
`
`1994-03-22
`
`MacGilp et al
`
`19
`
`5342625
`
`1994-08-30
`
`Hauer et al
`
`0206
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH MM.C.G./
`
`20
`
`5368854
`
`1994-11-29
`
`Donna Rennick
`
`21
`
`5411952
`
`1995-05-02
`
`Renee Kaswan
`
`22
`
`5424078
`
`1995-06-13
`
`Anthony Dziabo
`
`23
`
`5474919
`
`1995-12-12
`
`Chartrain et al
`
`24
`
`5474979
`
`1995-12-12
`
`Ding et al
`
`U.S. Application No. 08/243,279 and
`its entire prosecution history**
`
`25
`
`5504068
`
`1996-04-02
`
`Komiya et al
`
`26
`
`5540931
`
`1996-07-30
`
`Hewitt et al
`
`27
`
`5543393
`
`1996-08-06
`
`Kim et al
`
`28
`
`5589455
`
`1996-12-31
`
`Jong Woo
`
`29
`
`5591971
`
`1997-01-07
`
`Shahar et al
`
`30
`
`5614491
`
`1997-03-25
`
`Walch et al
`
`0207
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /M.M.C.G./
`
`31
`
`5639724
`
`1997-06-17
`
`Thomas Cavanak
`
`32
`
`5652212
`
`1997-07-29
`
`Cavanak et al
`
`33
`
`5719123
`
`1998-02-17
`
`Morley et al
`
`34
`
`5739105
`
`1998-04-14
`
`Kim et al
`
`35
`
`5753166
`
`1998-05-19
`
`Dalton et al
`
`36
`
`5766629
`
`1998-06-16
`
`Cho et al
`
`37
`
`5798333
`
`1998-08-25
`
`Bernard Sherman
`
`38
`
`5807820
`
`1998-09-15
`
`Elias et al
`
`39
`
`5827822
`
`1998-10-27
`
`Floch'h et al
`
`40
`
`5827862
`
`1998-10-27
`
`Yoshitaka Yamamura
`
`41
`
`5834017
`
`1998-11-10
`
`Cho et al
`
`0208
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`17618-US-BCON6-AP
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MM.C.G./
`
`42
`
`5843452
`
`1998-12-01
`
`Wiedmann et al
`
`43
`
`5843891
`
`1998-12-01
`
`Bernard Sherman
`
`44
`
`5858401
`
`1999-01-12
`
`Bhalani et al
`
`45
`
`5866159
`
`1999-02-02
`
`Hauer et al
`
`46
`
`5891846
`
`1999-04-06
`
`Ishida et al
`
`47
`
`5916589
`
`1999-06-29
`
`Hauer et al
`
`48
`
`5929030
`
`1999-07-27
`
`Hamied et al
`
`49
`
`5951971
`
`1999-09-14
`
`Kawashima et al
`
`50
`
`5962014
`
`1999-10-05
`
`Hauer et al
`
`51
`
`5962017
`
`1999-10-05
`
`Hauer et al
`
`52
`
`5962019
`
`1999-10-05
`
`Cho et al
`
`0209
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MM.C.G./
`
`53
`
`5977066
`
`1999-11-02
`
`Thomas Cavanak
`
`54
`
`5981479
`
`1999-11-09
`
`Ko et al
`
`55
`
`5981607
`
`1999-11-09
`
`Ding et al
`
`U.S. Application No. 09/008,924 and
`its entire prosecution history**
`
`56
`
`5998365
`
`1999-12-07
`
`Bernard Sherman
`
`57
`
`6004566
`
`1999-12-21
`
`Friedman et al
`
`58
`
`6007840
`
`1999-12-28
`
`Hauer et al
`
`59
`
`6008191
`
`1999-12-28
`
`Amarjit Singh
`
`60
`
`6008192
`
`1999-12-28
`
`Al-Razzak et al
`
`61
`
`6022852
`
`2000-02-08
`
`Klokkers et al
`
`62
`
`6024978
`
`2000-02-15
`
`Hauer et al
`
`63
`
`6046163
`
`2000-04-04
`
`Stuchlik et al
`
`0210
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./
`
`64
`
`6057289
`
`2000-05-02
`
`Nirmal Mulye
`
`65
`
`6159933
`
`2000-12-12
`
`Bernard Sherman
`
`66
`
`6197335
`
`2001-03-06
`
`Bernard Sherman
`
`67
`
`6254860
`
`2001-07-03
`
`Michael Garst
`
`68
`
`6254885
`
`2001-07-03
`
`Cho et al
`
`69
`
`6267985
`
`2001-07-31
`
`Chen et al
`
`70
`
`6284268
`
`2001-09-04
`
`Mishra et al
`
`71
`
`6294192
`
`2001-09-25
`
`Patel et al
`
`72
`
`6306825
`
`2001-10-23
`
`Thomas Cavanak
`
`73
`
`6323204
`
`2001-11-27
`
`James Burke
`
`74
`
`6346511
`
`2002-02-12
`
`Singh et al
`
`0211
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MM.C.G./
`
`75
`
`6350442
`
`2002-02-26
`
`Michael Garst
`
`76
`
`6413547
`
`2002-07-02
`
`Bennett et al
`
`77
`
`6420355
`
`2002-07-16
`
`Richter et al
`
`78
`
`6468968
`
`2002-10-22
`
`Cavanak et al
`
`79
`
`6475519
`
`2002-11-05
`
`Meinzer et al
`
`80
`
`6486124
`
`2002-11-26
`
`Olbrich et al
`
`81
`
`6544953
`
`2003-04-08
`
`Tsuzuki et al
`
`82
`
`6555526
`
`2003-04-29
`
`Toshihiko Matsuo
`
`83
`
`6562873
`
`2003-05-13
`
`Olejnik et al
`
`84
`
`6569463
`
`2003-03-27
`
`Patel et al
`
`85
`
`6582718
`
`2003-06-24
`
`Yoichi Kawashima
`
`0212
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONS DERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./
`
`86
`
`6656460
`
`2003-12-02
`
`Benita et al
`
`87
`
`6872705
`
`2005-03-29
`
`Robert Lyons
`
`88
`
`7202209
`
`2007-04-10
`
`James N. Chang
`
`89
`
`7276476
`
`2007-10-02
`
`Chang et al
`
`90
`
`7288520
`
`2007-10-30
`
`Chang et al
`
`91
`
`7297679
`
`2007-11-20
`
`James Chang
`
`92
`
`7501393
`
`2009-03-10
`
`Tien et al
`
`93
`
`8211855
`
`2012-07-03
`
`Chang et al
`
`94
`
`8288348
`
`2012-10-16
`
`Chang et al
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`U.S.PATENT APPLICATION PUBLICATIONS
`
`U.S. Application No. 11/181,428 and
`its entire prosecution history**
`
`U.S. Application No. 11/181,187 and
`its entire prosecution history**
`
`U.S. Application No. 11/255,821 and
`its entire prosecution history**
`
`U.S. Application No. 11/181,178 and
`its entire prosecution history**
`
`U.S. Application No. 11/161,218 and
`its entire prosecution history**
`
`U.S. Application No. 11/857,223 and
`its entire prosecution history**
`
`U.S. Application No. 11/917,448 and
`its entire prosecution history**
`
`Examiner
`Initial*
`
`Cite No
`
`Publication
`Number
`
`Kind Publication
`Code1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`0213
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`20010003589
`
`2001-06-14
`
`Neuer et al
`
`20010014665
`
`2001-08-16
`
`Fischer et al
`
`20010036449
`
`2001-11-01
`
`Michael Garst
`
`20020012680
`
`2002-01-31
`
`Patel et al
`
`20020013272
`
`2002-01-31
`
`Cavanak et al
`
`20020016290
`
`2002-02-07
`
`Floc'h et al
`
`20020016292
`
`2002-02-07
`
`Richter et al
`
`20020025927
`
`2002-02-28
`
`Olbrich et al
`
`20020045601
`
`2002-04-18
`
`Yoichi Kawashima
`
`10
`
`20020107183
`
`2002-08-08
`
`Petszulat et al
`
`11
`
`20020119190
`
`2002-08-29
`
`Meinzer et al
`
`0214
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./
`
`12
`
`20020165134
`
`2002-11-07
`
`Richter et al
`
`13
`
`20030021816
`
`2003-01-30
`
`Kang et al
`
`14
`
`20030044452
`
`2003-03-06
`
`Ryuji Ueno
`
`15
`
`20030055028
`
`2003-03-20
`
`Stergiopoulos et al
`
`16
`
`20030059470
`
`2003-03-27
`
`Rainer Muller
`
`17
`
`20030060402
`
`2003-03-27
`
`Cavanak et al
`
`18
`
`20030087813
`
`2003-05-08
`
`Or et al
`
`19
`
`20030104992
`
`2003-06-05
`
`Or et al
`
`20
`
`20030108626
`
`2003-06-12
`
`Benita et al
`
`21
`
`20030109425
`
`2003-06-12
`
`Or et al
`
`22
`
`20030109426
`
`2003-06-12
`
`Or et al
`
`0215
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./
`
`23
`
`20030133984
`
`2003-07-17
`
`Ambuhl et al
`
`24
`
`20030143250
`
`2003-07-31
`
`Hauer et al
`
`25
`
`20030147954
`
`2003-08-07
`
`Yang et al
`
`26
`
`20030166517
`
`2003-09-04
`
`Fricker et al
`
`27
`
`20050014691
`
`2005-01-20
`
`Bakhit et al
`
`28
`
`20050059583
`
`2005-03-17
`
`Andrew Acheampong
`
`U.S. Application No. 10/927,857 and
`its entire prosecution history**
`
`29
`
`20070015691
`
`2007-01-18
`
`James Chang
`
`U.S. Application No. 11/181,409 and
`its entire prosecution history**
`
`30
`
`20070027072
`
`2007-02-01
`
`Tien et al
`
`31
`
`20070087962
`
`2007-04-19
`
`Tien et al
`
`32
`
`20070149447
`
`2007-06-28
`
`Chang et al
`
`33
`
`20070299004
`
`2007-12-27
`
`Acheampong et al
`
`U.S. Application No. 11/679,934 and
`its entire prosecution history**
`
`U.S. Application No. 11/897,177 and
`its entire prosecution history**
`
`0216
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, MM.C.G./
`
`34
`
`20080039378
`
`2008-02-14
`
`Graham et al
`
`35
`
`20080070834
`
`2008-03-20
`
`Chang et al
`
`36
`
`20080146497
`
`2008-06-19
`
`Graham et al
`
`37
`
`20080207495
`
`2008-08-28
`
`Graham et al
`
`38
`
`20090131307
`
`2009-05-21
`
`Tien et al
`
`39
`
`20100279951
`
`2010-11-04
`
`Morgan et al
`
`40
`
`20110009339
`
`2011-01-13
`
`Rhett Schiffman
`
`41
`
`20110294744
`
`2011-12-01
`
`Morgan et al
`
`42
`
`20120270805
`
`2012-10-25
`
`Chang et al
`
`43
`
`20130059796
`
`2013-03-07
`
`Chang et al
`
`U.S. Application No. 11/781,095 and
`its entire prosecution history**
`
`U.S. Application No. 11/940,652 and
`its entire prosecution history**
`
`U.S. Application No. 11/858,200 and
`its entire prosecution history**
`
`U.S. Application No. 12/035,698 and
`its entire prosecution history**
`
`U.S. Application No. 12/361,335 and
`its entire prosecution history**
`
`U.S. Application No. 12/771,952 and
`its entire prosecution history**
`
`U.S. Application No. 12/759,431 and
`its entire prosecution history**
`
`U.S. Application No. 13/115,764 and
`its entire prosecution history**
`
`U.S. Application No. 13/536,479 and
`its entire prosecution history**
`
`U.S. Application No. 13/649,287 and
`its entire prosecution history**
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.
`FOREIGN PATENT DOCUMENTS
`
`0217
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MM.C.G '
`
`Examiner Cite
`Initial*
`No
`
`Foreign Document
`Number3
`
`Country
`Code2!
`
`Kind Publication
`Code4 Date
`
`Name of Patentee or
`Applicant of cited
`Document
`
`Pages,Columns, Lines
`where Relevant
`Passages or Relevant
`Figures Appear
`
`T5
`
`1
`
`19810655
`
`DE
`
`1999-09-16
`
`Eberhard-Karis-
`Universitat Tubingen
`Universitatskl
`
`2
`
`0471293
`
`3
`
`0547229
`
`4
`
`0760237
`
`EP
`
`EP
`
`EP
`
`1992-02-19
`
`ABBOTT
`LABORATORIES
`
`1993-01-07
`
`LLT Institute Co., Ltd.
`
`1997-03-05
`
`Cipla Limited
`
`5
`
`1995-031211
`
`WO
`
`1995-11-23
`
`Allergan Inc.
`
`6
`
`2000-000179
`
`WO
`
`2000-01-06
`
`Won Jin Biopharma Co.,
`Ltd
`
`7
`
`2001-032142
`
`WO
`
`2001-05-10
`
`Cipla Limited
`
`8
`
`2001-041671
`
`WO
`
`2001-06-14
`
`Transneuronix, Inc.
`
`9
`
`2002-009667
`
`WO
`
`2002-02-07
`
`Pharmasol GMBH
`
`10
`
`2002-049603
`
`WO
`
`2002-06-27
`
`LG Household & Health
`Care Ltd.
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`0218
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFEREKCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G
`
`11
`
`2003-030834
`
`WO
`
`2003-04-17
`
`Enanta Pharmaceuticals,
`Inc.
`
`12
`
`2003-053405
`
`WO
`
`2003-07-03
`
`Yissum Research
`Development Company of
`the Hebrew
`
`•
`
`•
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`NON-PATENT LITERATURE DOCUMENTS
`
`Examiner Cite
`Initials* No
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`T5
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`ABDULRAZIK, M. ET AL, Ocular Delivery of Cyclosporin A II. Effect of Submicron Emulsion's Surface Charge on
`Ocular Distribution of Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432, 11(6)
`
`ACHEAMPONG, ANDREW ET AL, Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland and
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog and Human eyes, 1996, 179
`
`•
`
`•
`
`ACHEAMPONG, ANDREW ET AL, Cyclosporine Distribution Into The Conjunctiva, Cornea, Lacrimal Gland, and
`
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes, Adv. Exp. Med. Biol., •
`
`1998, 1001-1004, 438
`
`ACHEAMPONG, ANDREW ET AL, Distribution of Cyclosporin A in Ocular Tissues After Topical Administration to •
`
`Albino Rabbits and Beagle Dogs, Current Eye Research, 1999, 91-103, 18(2)
`
`AKPEK, ESEN KARAMURSEL ET AL, A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant
`Atopic Keratoconjunctivitis, Ophthalmology, 2004, 476-482, 111
`
`ANGELOV, O. ET AL, Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion, Adv Exp Med Biol, 1998,
`991-995, 438
`
`ANGELOV, O. ET AL, Safety Assessment of Cyclosporine Ophthalmic Emulsion in Rabbits and Dogs, Xlth Congress
`of the European Society of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., HU
`
`•
`
`•
`
`•
`
`0219
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`17618-US-BCON6-AP
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G,/
`
`8
`
`9
`
`ARDIZZONE, SANDRO ET AL, A Practical Guide to the Management of Distal Ulcerative Colitis, Drugs, 1998,
`519-542, 55(4)
`
`•
`
`BANIC, MARKO ET AL, Effect of Cyclosporine in a Murine Model of Experimental Colitis, Digestive Diseases and •
`
`Sciences, June 2002, 1362-1368, 47(6)
`
`10
`
`BONINI, S. ET AL, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18
`
`11
`
`BREWSTER, MARCUS ET AL, Enhanced Delivery of Ganciclovir to the Brain Through the Use of Redox Targeting,
`Antimicrobial Agents and Chemotherapy, Apr 1994, 817-823, 38(4)
`
`BREWSTER, MARCUS ET AL, Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl-(2,-cyclodextrin-
`Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions,
`Journal of Pharmaceutical Sciences, March 1997, 335-339, 86(3)
`
`•
`
`•
`
`•
`
`12
`
`13
`
`BREWSTER, MARCUS ET AL, Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropyl-(2,-
`
`cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse, Journal of Pharmaceutical Sciences, •
`
`October 1995, 1154-1159, 84(10)
`
`14
`
`BRINKMEIER, THOMAS ET AL, Pyodermatitis-Pyostomatitis Vegetans: A Clinical Course of Two Decades with
`Response to Cyclosporine and Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81
`
`•
`
`15
`
`16
`
`CASTILLO, JOSE M. BENITEZ DEL ET AL, Influence of Topical Cyclosporine A and Dissolvent on Corneal Epithelium •
`
`Permeability of Fluorescein, Documenta Ophthalmologica, 1995, 49-55, 91
`
`CHEEKS, LISA ET AL, Influence of Vehicle and Anterior Chamber Protein Concentration on Cyclosporine Penetration •
`
`Through the Isolated Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7)
`
`17
`
`Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An 2000-492678 & JP2000/143542, 2000, 2 Pages
`
`•
`
`18
`
`DING, SHULIN ET AL, Cyclosporine Ophthalmic O/W emulsion: Formulation and Emulsion Characterization, Pharm •
`
`Res, 1997, 1 page, 14 (11)
`
`0220
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /M.M.C.G./
`
`19
`
`DONNENFELD, ERIC D., The Economics Of Using Restasis, Ophthalmology Management, 10/2003, 3 pages, US
`
`20
`
`DROSOS, A. A. ET AL, Efficacy and Safety of Cyclosporine-A Therapy for Primary Sjogren's Syndrome, Ter. Arkh.,
`1998, 77-80, 60(4)
`
`•
`
`•
`
`21
`
`DROSOS, A.A. ET AL, Cyclosporin A Therapy in Patients with Primary Sjogren's Syndrome: Results at One Year, •
`
`Scand J Rheumatology, 1986, 246-249, 61
`
`22
`
`EISEN, DRORE ET AL, Topical Cyclosporine for Oral Mucosal Disorders, J Am Acad Dermatol, Dec. 1990,
`1259-1264, 23
`
`•
`
`23
`
`EPSTEIN, JOEL ET AL, Topical Cyclosporine in a Bioadhesive for Treatment of Oral Lichenoid Muscosal Reactions, •
`
`Oral Surg Oral Med Oral Pathol Oral, 1996, 532-536, 82
`
`24
`
`ERDMANN, S. ET AL, Pemphigus Vulgaris Der Mund- Und Kehlkopfschleimhaut Pemphigus Vulgaris of the Oral
`Mucosa and the Larynx, H+G Zeitschrift Fuer Hautkrankheiten, 1997, 283-286, 72(4)
`
`25
`
`FDA Concludes Restasis (Cyclosporine) Not Effective for Dry Eye (6/18/1999). Accessed online at http://www.
`dryeyeinfo.org/Restasis_Cyclosporine.htm on 8/14/09. 1 Page
`
`26
`
`GAETA, G.M. ET AL, Cyclosporin Bioadhesive Gel in the Topical Treatment of Erosive Oral Lichen Planus,
`International Journal of Immunopathology and Pharmacology, 1994, 125-132, 7(2)
`
`•
`
`•
`
`•
`
`27
`
`GIPSON, ILENE ET AL, Character of Ocular Surface Mucins and Their Alteration in Dry Eye Disease, The Ocular •
`
`Surface, April 2004, 131-148, 2(2)
`
`28
`
`GREMSE, DAVID ET AL, Ulcerative Colitis in Children, Pediatr Drugs, 2002, 807-815, 4(12)
`
`29
`
`GUNDUZ, KAAN ET AL, Topical Cyclosporin Treatment of Keratoconjunctivitis Sicca in Secondary Sjogren's
`Syndrome, Acta Ophthalmologica, 1994, 438-442, 72
`
`•
`
`•
`
`0221
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MM.C.G./
`
`30
`
`http://web.archive.org/web/2001030625323/http://www.surfactant.co.kr/surfactants/pegester.html, 2001, 6 Pages,
`retrieved on 7/05/2008
`
`31
`
`HUNTER, P.A. ET AL, Cyclosporin A Applied Topically to the Recipient Eye Inhibits Corneal Graft Rejection, Clin Exp
`Immunol, 1981, 173-177, 45
`
`32
`
`JUMAA, MUHANNAD ET AL, Physicochemical Properties and Hemolytic Effect of Different Lipid Emulsion
`Formulations Using a Mixture of Emulsifiers, Pharmaceutica Acta Helvetiae, 1999, 293-301, 73
`
`•
`
`•
`
`•
`
`33
`
`KANAI, A. ET AL, The Effect on the Cornea of Alpha Cyclodextrin Vehicle for Eye Drops, Transplantation Proceedings, •
`
`Febraury 1989, 3150-3152, Vol. 21
`
`34
`
`KANPOLAT, AYFER ET AL, Penetration of Cyclosporin A into the Rabbit Cornea and Aqueous Humor after Topical
`Drop and Collagen Shield Administration, Cornea/External Disease, April 1994, 119-122, 20(2)
`
`35
`
`KAUR, RABINDER ET AL, Solid Dispersions of Drugs in Polyocyethylene 40 Stearate: Dissolution Rates and Physico-
`Chemical Interactions, Journal of Pharmacy and Pharmacology, December 1979, 48P
`
`•
`
`•
`
`36
`
`KUWANO, MITSUAKI ET AL, Cyclosporine A Formulation Affects Its Ocular Distribution in Rabbits, Pharmaceutical •
`
`Research, January 2002, 108-111, 19(1)
`
`37
`
`Lambert Technologies Corp. Material Safety Data Sheet for LUMULSE ™ POE-40 MS KP, last revision 8/22/2003. 3
`pages
`
`•
`
`38
`
`39
`
`LEIBOVITZ, Z. ET AL., Our Experience In Processing Maize (Corn) Germ Oil, Journal Of The American Oil Chemists •
`
`Society, 02/1983, 395-399, 80 (2), US
`
`LIXIN, XIE ET AL, Effect Of Cyclosporine A Delivery System in Corneal Transplantation, Chinese Medical Journal, •
`
`2002, 110-113, 115 (1), US
`
`40
`
`LOPATIN, D.E., Chemical Compositions and Functions of Saliva, 8/24/2001, 31 Pages
`
`•
`
`0222
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MM.C.G./
`
`41
`
`LYONS, R.T. ET AL, Influence of Three Emulsion Formulation Parameters on the Ocular Bioavailability of
`Cyclosporine A in Albino Rabbits, Am Assoc Pharm Sci, 2000, 1 Page, 2(4)
`
`•
`
`42
`
`43
`
`PEDERSEN, ANNE MARIE ET AL, Primary Sjogren's Syndrome: Oral Aspects on Pathogenesis, Diagnostic Criteria, •
`
`Clinical Features and Approaches for Therapy, Expert Opin Pharma, 2001, 1415-1436, 2(9)
`
`PHILLIPS, THOMAS ET AL, Cyclosporine Has a Direct Effect on the Differentiation of a Mucin-Secreting Cell Line, •
`
`Journal of Cellular Physiology, 2000, 400-408, 184
`
`44
`
`PRESENT, D.H. ET AL, Cyclosporine and Other Immunosuppressive Agents: Current and Future Role in the
`Treatment of Inflammatory Bowel Disease, American Journal of Gastroenterology, 1993, 627-630, 88(5)
`
`45
`
`Restasis ® Product Information Sheet, Allergan, Inc., 2009, 5 Pages
`
`46
`
`Restasis® Increasing Tear Production, Retrieved on 08/14/2009, http://www.restasisprofessional.com/_clinical/
`clinical_increasing.htm 3 pages
`
`•
`
`•
`
`•
`
`47
`
`ROBINSON, N.A. ET AL, Desquamative Gingivitis: A Sign of Mucocutaneous Disorders - a Review, Australian Dental •
`
`Journal, 2003, 205-211, 48(4)
`
`48
`
`RUDINGER, J., Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence, Peptide
`Hormones, 1976, 1-7
`
`49
`
`SALL, KENNETH ET AL, Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic
`Emulsion in Moderate to Severe Dry Eye Disease, Ophthalmology, 2000, 631-639, 107
`
`50
`
`SANDBORN, WILLIAM ET AL, A Placebo-Controlled Trial of Cyclosporine Enemas for Mildly to Moderately Active
`Left-Sided Ulcerative Colitis, Gastroenterology, 1994, 1429-1435, 106
`
`51
`
`SANDBORN, WILLIAM ET AL, Cyclosporine Enemas for Treatment-Resistant, Mildly to Moderately Active, Left-Sided
`Ulcerative Colitis, American Journal of Gastroenterology, 1993, 640-645, 88(5)
`
`•
`
`•
`
`•
`
`•
`
`0223
`
`

`
`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`13967163
`
`2013-08-14
`
`13967163 ~GAU: 1658
`
`First Named Inventor ACHEAMPONG,ANDREW
`Art Unit
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Doc